论文部分内容阅读
目的观察孟鲁司特钠治疗儿科哮喘患儿的临床疗效。方法随机抽取2016年2月-2017年2月医院收治的儿科哮喘患儿90例,随机分为M组(n=45)和N组(n=45)。N组患儿给予常规治疗,M组患儿在N组治疗的基础上给予孟鲁司特钠治疗。对比2组患儿的治疗效果、临床症状(气喘、胸闷、咳嗽、咯痰)消失时间、肺功能指标及不良反应发生率。结果 M组总有效率为97.8%高于N组的75.6%,差异有统计学意义(χ2=9.6154,P<0.01)。M组气喘、胸闷、咳嗽、咯痰症状消失时间短于N组,差异均有统计学意义(P<0.01)。M组残气量/肺总量(RV/TLC)、最大呼气量(PEF)、残气量(RV)、用力呼气量占用力肺活量比值(FEV1/FVC)、用力肺活量(FVC)、用力呼气量(FEV1)均优于N组,差异均有统计学意义(P<0.01)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论孟鲁司特钠治疗儿科哮喘临床疗效显著,改善了患儿肺功能,缩短了患儿的治疗时间,且无明显不良反应发生,值得临床借鉴和推广。
Objective To observe the clinical efficacy of montelukast sodium in pediatric asthma children. Methods Totally 90 children with pediatric asthma admitted from February 2016 to February 2017 in our hospital were randomly divided into M group (n = 45) and N group (n = 45). N group of children given conventional treatment, M group of children in the N group on the basis of treatment given montelukast sodium treatment. The therapeutic effect, the disappearance time of clinical symptoms (asthma, chest tightness, cough, expectoration), the indexes of lung function and the incidence of adverse reactions were compared between the two groups. Results The total effective rate in group M was 97.8%, which was significantly higher than that in group N (χ2 = 9.6154, P <0.01). M group asthma, chest tightness, cough, expectoration symptoms disappear shorter than the N group, the difference was statistically significant (P <0.01). M group, RV / TLC, PEF, RV, FEV1 / FVC, FVC, (FEV1) were better than the N group, the difference was statistically significant (P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Montelukast sodium treatment of pediatric asthma clinical significant effect, improve children’s lung function, shorten the treatment of children with no obvious adverse reactions, it is worth learning and promotion.